卫光生物(002880) - 2018年4月11日投资者关系活动记录表

Group 1: Financial Performance - The main reason for the decline in gross profit margin in 2017 was due to the implementation of the "two-invoice system" and the rising cost of raw plasma, leading to increased direct material costs [2][3] - The company collected a total of 342.41 tons of plasma in 2017, with an expectation to maintain the average growth rate of plasma collection in 2018 [3][4] Group 2: Market Trends - The price trend for domestic and imported human immunoglobulin is expected to show a slight decline in the future due to increased production capacity [3] - The average usage of immunoglobulin in China is significantly lower than in developed countries, indicating substantial market potential [3] Group 3: Accounts Receivable - The increase in accounts receivable at year-end was primarily due to sales on credit to long-term cooperative customers, with most receivables aged within three months and expected to be collected within six months [3][4] Group 4: Product Development and Marketing - The company successfully launched the allergen immunoglobulin product (brand name: Min Er Kang), which has good market prospects [4][5] - The sales team currently consists of over 20 members, with plans to strengthen the sales force and adjust marketing strategies in response to the "two-invoice system" [4][5] Group 5: Future Strategies - The company plans to establish an external development platform to achieve growth through mergers, acquisitions, and collaborative operations based on market conditions [5]